Study of a patient with Myelodysplastic/myeloproliferative neoplasm with co-morbid neutrophilia and a novel NCOR1: : GLYR1 fusion gene
10.3760/cma.j.cn511374-20230202-00048
- VernacularTitle:伴 NCOR1：： GLYR1融合基因MDS/MPN伴中性粒细胞增多1例患者的研究
- Author:
Yutian LEI
1
;
Xiaoli ZHAO
;
Huihui ZHAO
;
Yu CHENG
;
Shuai WANG
;
Jianyong LI
;
Yu ZHU
Author Information
1. 南京医科大学第一附属医院，江苏省人民医院血液科，南京 200029
- Keywords:
NCOR1: : GLYR1 fusion gene;
RNA sequencing;
MDS/MPN with neutrophilia
- From:
Chinese Journal of Medical Genetics
2024;41(4):404-410
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the genetic background for a patient with refractory myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with co-morbid neutrophilia patient.Methods:A MDS/MPN patient who was admitted to the First Affiliated Hospital of Nanjing Medical University in May 2021 was selected as the study subject. RNA sequencing was carried out to identify fusion genes in his peripheral blood mononuclear cells. Fusion gene sequence was searched through transcriptome-wide analysis with a STAR-fusion procedure. The novel fusion genes were verified by quantitative real-time PCR and Sanger sequencing.Results:The patient, a 67-year-old male, had progressive thrombocytopenia. Based on the morphological and molecular examinations, he was diagnosed as MDS/MPN with co-morbid neutropenia, and was treated with demethylating agents and Bcl-2 inhibitors. Seventeen months after the diagnosis, he had progressed to AML. A novel fusion gene NCOR1: : GLYR1 was identified by RNA-sequencing in his peripheral blood sample, which was verified by quantitative real-time PCR and Sanger sequencing. The patient had attained morphological remission after a DCAG regimen (a combinatory chemotherapy of decitabine, cytarabine, aclarubicin and granulocyte colony-stimulating factors) plus Chidamide treatment. A significant decrease in the NCOR1: : GLYR1 expression was revealed by quantitative real-time PCR at post-chemotherapy evaluation. Conclusion:NCOR1: : GLYR1 gene is considered as the pathogenic factor for the MDS/MPN patient with neutropenia.
